Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- 3-year event-free survival (EFS) rate
研究概览
简要总结
For resectable non-small cell lung cancer, neoadjuvant immunochemotherapy plus adjuvant immunotherapy or adjuvant immunochemotherapy is usually used in clinical practice. However, it is unclear whether therapeutic strategy is superior. This trial aims to compare the efficacy and safety of these two strategies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient shall sign the Informed Consent Form.
- •Aged 18 ≥ years.
- •Histological or cytological diagnosis of NSCLC by needle biopsy, and stage II-IIIB (N2) confirmed by imageological examinations (CT, PET-CT or EBUS).
- •Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or
- •Life expectancy is at least 12 weeks.
- •At least 1 measurable lesion according to RECIST 1.
- •Patients with good function of other main organs (liver, kidney, blood system, etc.)
- •Patients with lung function can tolerate surgery;
- •Without systematic metastasis (including M1a, M1b and M1c);
- •Fertile female patients must voluntarily use effective contraceptives not less than 120 days after chemotherapy or the last dose of immunotherapy (whichever is later) during the study period, and urine or serum pregnancy test results within 7 days prior to enrollment are negative.
- •Unsterilized male patients must voluntarily use effective contraception during the study period not less than 120 days after chemotherapy or the last dose of immunotherapy (whichever is later).
排除标准
- •Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment;
- •Participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (>= NYHA) Grade II), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;
- •With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;
- •Participants who are allergic to the test drug or any auxiliary materials;
- •Participants with Interstitial lung disease currently;
- •Participants with active hepatitis B, hepatitis C or HIV;
- •Pregnant or lactating women;
- •Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
- •Participated in another therapeutic clinical study;
- •Other factors that researchers think it is not suitable for enrollment.
研究组 & 干预措施
Perioperative immunotherapy
In this arm, patients will receive neoadjuvant immunochemotherapy and adjuvant immunotherapy.
干预措施: Nab-paclitaxel (Drug)
Perioperative immunotherapy
In this arm, patients will receive neoadjuvant immunochemotherapy and adjuvant immunotherapy.
干预措施: TQB2450 (Drug)
Perioperative immunotherapy
In this arm, patients will receive neoadjuvant immunochemotherapy and adjuvant immunotherapy.
干预措施: Carboplatin (Drug)
Perioperative immunotherapy
In this arm, patients will receive neoadjuvant immunochemotherapy and adjuvant immunotherapy.
干预措施: Pemetrexed (Drug)
Perioperative immunotherapy
In this arm, patients will receive neoadjuvant immunochemotherapy and adjuvant immunotherapy.
干预措施: Surgery (Procedure)
Adjuvant immunotherapy
In this arm, patients will receive adjuvant immunochemothrapy and immunotherapy
干预措施: TQB2450 (Drug)
Adjuvant immunotherapy
In this arm, patients will receive adjuvant immunochemothrapy and immunotherapy
干预措施: Carboplatin (Drug)
Adjuvant immunotherapy
In this arm, patients will receive adjuvant immunochemothrapy and immunotherapy
干预措施: Pemetrexed (Drug)
Adjuvant immunotherapy
In this arm, patients will receive adjuvant immunochemothrapy and immunotherapy
干预措施: Nab-paclitaxel (Drug)
Adjuvant immunotherapy
In this arm, patients will receive adjuvant immunochemothrapy and immunotherapy
干预措施: Surgery (Procedure)
结局指标
主要结局
3-year event-free survival (EFS) rate
时间窗: Up to 48 months
Event-free survival (EFS) is defined as the length of time (months) from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
次要结局
- Objective response rate (ORR)(Up to 6 months)
- Pathological complete response (pCR)(Up to 8 months)
- Major pathologic response (MPR)(Up to 8 months)
- 5-year event-free survival (EFS) rate(Up to 72 months)
- 5-year overall survival (OS)(Up to 72 months)
- Event-free survival (EFS)(Up to 72 months)
- Adverse event rate(Up to 36 months)
- Overall survival (OS)(Up to 72 months)
- Health related quality of life (HRQol)(Up to 36 months)
研究者
Peng Zhang
Professor
Shanghai Pulmonary Hospital, Shanghai, China